Now showing items 1-12 of 12

    • Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. 

      Smyth, EC; Fassan, M; Cunningham, D; Allum, WH; Okines, AFC; Lampis, A; Hahne, JC; Rugge, M; Peckitt, C; Nankivell, M; Langley, R; Ghidini, M; Braconi, C; Wotherspoon, A; Grabsch, HI; Valeri, N (2016-08)
      <h4>Purpose</h4>The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with ...
    • EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. 

      Smyth, EC; Vlachogiannis, G; Hedayat, S; Harbery, A; Hulkki-Wilson, S; Salati, M; Kouvelakis, K; Fernandez-Mateos, J; Cresswell, GD; Fontana, E; Seidlitz, T; Peckitt, C; Hahne, JC; Lampis, A; Begum, R; Watkins, D; Rao, S; Starling, N; Waddell, T; Okines, A; Crosby, T; Mansoor, W; Wadsley, J; Middleton, G; Fassan, M; Wotherspoon, A; Braconi, C; Chau, I; Vivanco, I; Sottoriva, A; Stange, DE; Cunningham, D; Valeri, N (2020-11-16)
      <h4>Objective</h4>Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between ...
    • Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. 

      Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; Hahne, JC; Vlachogiannis, G; Hedayat, S; Marchetti, S; Lampis, A; Damavandi, MD; Lote, H; Rana, I; Williams, A; Eccles, SA; Fontana, E; Collins, D; Eltahir, Z; Rao, S; Watkins, D; Starling, N; Thomas, J; Kalaitzaki, E; Fotiadis, N; Begum, R; Bali, M; Rugge, M; Temple, E; Fassan, M; Chau, I; Braconi, C; Valeri, N (2018-08)
      <h4>Objective</h4>Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for ...
    • KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. 

      Sclafani, F; Chau, I; Cunningham, D; Hahne, JC; Vlachogiannis, G; Eltahir, Z; Lampis, A; Braconi, C; Kalaitzaki, E; De Castro, DG; Wotherspoon, A; Capdevila, J; Glimelius, B; Tarazona, N; Begum, R; Lote, H; Hulkki Wilson, S; Mentrasti, G; Brown, G; Tait, D; Oates, J; Valeri, N (2018-01-23)
      There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples ...
    • Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. 

      Khan, KH; Cunningham, D; Werner, B; Vlachogiannis, G; Spiteri, I; Heide, T; Mateos, JF; Vatsiou, A; Lampis, A; Damavandi, MD; Lote, H; Huntingford, IS; Hedayat, S; Chau, I; Tunariu, N; Mentrasti, G; Trevisani, F; Rao, S; Anandappa, G; Watkins, D; Starling, N; Thomas, J; Peckitt, C; Khan, N; Rugge, M; Begum, R; Hezelova, B; Bryant, A; Jones, T; Proszek, P; Fassan, M; Hahne, JC; Hubank, M; Braconi, C; Sottoriva, A; Valeri, N (2018-10)
      Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. ...
    • miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. 

      Anandappa, G; Lampis, A; Cunningham, D; Khan, KH; Kouvelakis, K; Vlachogiannis, G; Hedayat, S; Tunariu, N; Rao, S; Watkins, D; Starling, N; Braconi, C; Darvish-Damavandi, M; Lote, H; Thomas, J; Peckitt, C; Kalaitzaki, R; Khan, N; Fotiadis, N; Rugge, M; Begum, R; Rana, I; Bryant, A; Hahne, JC; Chau, I; Fassan, M; Valeri, N (2019-07)
      <h4>Purpose</h4>Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. <i>RAS</i> status and tumor location (sidedness) are predictive markers of patients' response to anti-EGFR mAbs. ...
    • MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. 

      Lampis, A; Carotenuto, P; Vlachogiannis, G; Cascione, L; Hedayat, S; Burke, R; Clarke, P; Bosma, E; Simbolo, M; Scarpa, A; Yu, S; Cole, R; Smyth, E; Mateos, JF; Begum, R; Hezelova, B; Eltahir, Z; Wotherspoon, A; Fotiadis, N; Bali, MA; Nepal, C; Khan, K; Stubbs, M; Hahne, JC; Gasparini, P; Guzzardo, V; Croce, CM; Eccles, S; Fassan, M; Cunningham, D; Andersen, JB; Workman, P; Valeri, N; Braconi, C (2018-03)
      BACKGROUND & AIMS:Cholangiocarcinomas (CCA) are resistant to chemotherapy, so new therapeutic agents are needed. We performed a screen to identify small-molecule compounds that are active against CCAs. Levels of microRNA ...
    • Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. 

      Carotenuto, P; Hedayat, S; Fassan, M; Cardinale, V; Lampis, A; Guzzardo, V; Vicentini, C; Scarpa, A; Cascione, L; Costantini, D; Carpino, G; Alvaro, D; Ghidini, M; Trevisani, F; Te Poele, R; Salati, M; Ventura, S; Vlachogiannis, G; Hahne, JC; Boulter, L; Forbes, SJ; Guest, RV; Cillo, U; Said-Huntingford, I; Begum, R; Smyth, E; Michalarea, V; Cunningham, D; Rimassa, L; Santoro, A; Roncalli, M; Kirkin, V; Clarke, P; Workman, P; Valeri, N; Braconi, C (2020-09-10)
      <h4>Background and aims</h4>Changes in single microRNA (miRNA) expression have been associated with chemo-resistance in biliary tract cancers (BTCs). However, a global assessment of the dynamic role of the microRNome has ...
    • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. 

      Vlachogiannis, G; Hedayat, S; Vatsiou, A; Jamin, Y; Fernández-Mateos, J; Khan, K; Lampis, A; Eason, K; Huntingford, I; Burke, R; Rata, M; Koh, D-M; Tunariu, N; Collins, D; Hulkki-Wilson, S; Ragulan, C; Spiteri, I; Moorcraft, SY; Chau, I; Rao, S; Watkins, D; Fotiadis, N; Bali, M; Darvish-Damavandi, M; Lote, H; Eltahir, Z; Smyth, EC; Begum, R; Clarke, PA; Hahne, JC; Dowsett, M; de Bono, J; Workman, P; Sadanandam, A; Fassan, M; Sansom, OJ; Eccles, S; Starling, N; Braconi, C; Sottoriva, A; Robinson, SP; Cunningham, D; Valeri, N (2018-02)
      Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from ...
    • Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. 

      Sclafani, F; Chau, I; Cunningham, D; Peckitt, C; Lampis, A; Hahne, JC; Braconi, C; Tabernero, J; Glimelius, B; Cervantes, A; Begum, R; Gonzalez De Castro, D; Hulkki Wilson, S; Eltahir, Z; Wotherspoon, A; Tait, D; Brown, G; Oates, J; Valeri, N (2015-09)
      <h4>Background</h4>Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary ...
    • Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. 

      Sclafani, F; Chau, I; Cunningham, D; Lampis, A; Hahne, JC; Ghidini, M; Lote, H; Zito, D; Tabernero, J; Glimelius, B; Cervantes, A; Begum, R; De Castro, DG; Wilson, SH; Peckitt, C; Eltahir, Z; Wotherspoon, A; Tait, D; Brown, G; Oates, J; Braconi, C; Valeri, N (2016-09)
      Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, ...
    • A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. 

      Smyth, EC; Nyamundanda, G; Cunningham, D; Fontana, E; Ragulan, C; Tan, IB; Lin, SJ; Wotherspoon, A; Nankivell, M; Fassan, M; Lampis, A; Hahne, JC; Davies, AR; Lagergren, J; Gossage, JA; Maisey, N; Green, M; Zylstra, JL; Allum, WH; Langley, RE; Tan, P; Valeri, N; Sadanandam, A (2018-12)
      <h4>Background</h4>Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity ...